|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Current assets | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Short-term investments | |||||||||||||||||||
| Marketable securities | |||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||
| Inventory, net | |||||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Long-term assets | |||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||||
| Intangible assets, net | |||||||||||||||||||
| Long-term investments | |||||||||||||||||||
| Long-term marketable securities | |||||||||||||||||||
| Other long-term assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| Liabilities and stockholders’ equity | |||||||||||||||||||
| Current liabilities | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Accrued compensation | |||||||||||||||||||
| Accrued clinical trial site costs | |||||||||||||||||||
| Common stock purchase liability | |||||||||||||||||||
| Operating lease liabilities | |||||||||||||||||||
| Accrued interest payable | |||||||||||||||||||
| Contingent liability for Essentialis purchase price | |||||||||||||||||||
| Other current liabilities | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Long-term liabilities | |||||||||||||||||||
| Warrant liability | |||||||||||||||||||
| Contingent liability for Essentialis purchase price | |||||||||||||||||||
| Common stock purchase liability | |||||||||||||||||||
| Long-term debt, net | |||||||||||||||||||
| Long-term lease liabilities | |||||||||||||||||||
| Other long-term liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 51,718,149 and 52,286,881 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | |||||||||||||||||||
| Additional paid-in-capital | |||||||||||||||||||
| Accumulated other comprehensive income (loss) | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
